The GIP receptor component may further modulate appetite, though its precise effects on reward-related eating behaviour in humans are not yet fully established and remain an active area of research
Finally, they will discuss the patients past experience and troubles with weight loss
These effects appear to be mediated by several mechanisms, including reduced systemic inflammation and improved lipid metabolism
Restarting: If a patient stops for more than 2 weeks, they should ideally restart at 0.25 mg to avoid severe side effects, rather than resuming immediately at 0.5 mg
The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management